

SUPPORT FOR THE AMENDMENTS

Support for the amendments is inherent in the specification. The marked-up version of the amendments to Claims 1-4, 6, and 13-18 is found on a separate sheet attached to this amendment and titled "Marked-Up Version of Rewritten Claims". Support for the amendment to the structures in Claim 3 can be found in Claims 1 and 2. No new matter would be added upon entry of this amendment.

Claims 1-18 will be pending upon entry of this amendment.

REMARKS

Applicants have amended the above-identified application to recite the applications to which priority is claimed, as suggested by the Examiner.

Except for the provisos added to Claim 1, the above amendments are not intended to limit the scope of the present claims. They are, instead, intended to correct clerical errors and clarify the claim language. The proviso at the end of Claim 1 was added to prevent any potential conflict with WO94/02477 and U.S. 5,317,103.

The rejection of Claims 1-5 and 7-18 under 35 U.S.C. §112, second paragraph, has been obviated by appropriate amendment.

Applicants have removed "contain" and "containing" from the claims. Withdrawal of this rejection is respectfully requested.

The obviousness-type double patenting rejection of the Claims over U.S. 6,339,099 has been obviated by appropriate amendment.

The proviso added to Claim 1 removes the subject matter of U.S. 6,339,099. Withdrawal of this rejection is respectfully requested.

In view of the foregoing, Applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited.

Respectfully submitted,



Jing S. Belfield, Ph.D.
Agent for Applicants
Registration No. 45,914
Telephone 302/467-5262

Bristol-Myers Squibb Pharma Company
C/o Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000


Marked-Up Version of Rewritten Claims 1-4, 6, and 13-18

Application No.: 09/924,381

Docket No. DM-6904-A

The subject matter to be added is in bold and underlined and the subject matter to be deleted is in bold and has been bracketed with square brackets.

1. (Amended) A compound of formula I:



or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

ring D is selected from $-\text{CH}_2\text{N}=\text{CH}-$, $-\text{CH}_2\text{CH}_2\text{N}=\text{CH}-$, and a 5-6 membered aromatic ring consisting of carbon atoms and [system containing from] 0-2 heteroatoms selected from the group N, O, and S;


provided that ring D is other than a 5-membered aromatic ring when M is structure q, t, or u;


ring D is substituted with 0-2 R, provided that when ring D is unsubstituted, [it contains] at least one ring heteratom is present therein;

ring E consists of [contains] 0-2 N atom and is substituted by 0-1 R

R is selected from Cl, F, Br, I, OH, C_{1-3} alkoxy, NH_2 , $\text{NH}(\text{C}_{1-3} \text{ alkyl})$, $\text{N}(\text{C}_{1-3} \text{ alkyl})_2$, CH_2NH_2 , $\text{CH}_2\text{NH}(\text{C}_{1-3} \text{ alkyl})$, $\text{CH}_2\text{N}(\text{C}_{1-3} \text{ alkyl})_2$, $\text{CH}_2\text{CH}_2\text{NH}_2$, $\text{CH}_2\text{CH}_2\text{NH}(\text{C}_{1-3} \text{ alkyl})$, and $\text{CH}_2\text{CH}_2\text{N}(\text{C}_{1-3} \text{ alkyl})_2$;

M is selected from the group:





J is O or S;

J^a is NH or NR^{1a} ;

Z is selected from a bond, C_{1-4} alkylene, $(CH_2)_rO(CH_2)_r$, $(CH_2)_rNR^3(CH_2)_r$, $(CH_2)_rC(O)(CH_2)_r$, $(CH_2)_rC(O)O(CH_2)_r$,

$(\text{CH}_2)_r\text{OC}(\text{O})(\text{CH}_2)_r$, $(\text{CH}_2)_r\text{C}(\text{O})\text{NR}^3(\text{CH}_2)_r$,
 $(\text{CH}_2)_r\text{NR}^3\text{C}(\text{O})(\text{CH}_2)_r$, $(\text{CH}_2)_r\text{OC}(\text{O})\text{O}(\text{CH}_2)_r$,
 $(\text{CH}_2)_r\text{OC}(\text{O})\text{NR}^3(\text{CH}_2)_r$, $(\text{CH}_2)_r\text{NR}^3\text{C}(\text{O})\text{O}(\text{CH}_2)_r$,
 $(\text{CH}_2)_r\text{NR}^3\text{C}(\text{O})\text{NR}^3(\text{CH}_2)_r$, $(\text{CH}_2)_r\text{S}(\text{O})_p(\text{CH}_2)_r$,
 $(\text{CH}_2)_r\text{SO}_2\text{NR}^3(\text{CH}_2)_r$, $(\text{CH}_2)_r\text{NR}^3\text{SO}_2(\text{CH}_2)_r$, and
 $(\text{CH}_2)_r\text{NR}^3\text{SO}_2\text{NR}^3(\text{CH}_2)_r$, provided that Z does not form a
N-N, N-O, N-S, NCH₂N, NCH₂O, or NCH₂S bond with ring M
or group A;

R^{1a} and R^{1b} are independently **[absent]** H or selected from
- $(\text{CH}_2)_r\text{-R}^{1'}$, $-\text{CH}=\text{CH}-\text{R}^{1'}$, $\text{NCH}_2\text{R}^{1'}$, $\text{OCH}_2\text{R}^{1'}$, $\text{SCH}_2\text{R}^{1'}$,
 $\text{NH}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1'}$, $\text{O}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1'}$, and $\text{S}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1'}$;

alternatively, R^{1a} and R^{1b}, when attached to adjacent carbon
atoms, together with the atoms to which they are
attached form a 5-8 membered saturated, partially
saturated or unsaturated ring substituted with 0-2 R⁴
and which **[contains from]** consists of carbon atoms and
0-2 heteroatoms selected from the group consisting of
N, O, and S;

alternatively, when Z is C(O)NH and R^{1a} is attached to a ring
carbon adjacent to Z, then R^{1a} is a C(O) which replaces
the amide hydrogen of Z to form a cyclic imide;

R^{1'} is selected from H, C₁₋₃ alkyl, F, Cl, Br, I, -CN, -CHO,
 $(\text{CF}_2)_r\text{CF}_3$, $(\text{CH}_2)_r\text{OR}^2$, NR^2R^{2a} , $\text{C}(\text{O})\text{R}^{2c}$, $\text{OC}(\text{O})\text{R}^2$,
 $(\text{CF}_2)_r\text{CO}_2\text{R}^{2c}$, $\text{S}(\text{O})_p\text{R}^{2b}$, $\text{NR}^2(\text{CH}_2)_r\text{OR}^2$, $\text{C}[\text{H}](=\text{NR}^{2c})\text{NR}^2\text{R}^{2a}$,
 $\text{NR}^2\text{C}(\text{O})\text{R}^{2b}$, $\text{NR}^2\text{C}(\text{O})\text{NHR}^{2b}$, $\text{NR}^2\text{C}(\text{O})_2\text{R}^{2a}$, $\text{OC}(\text{O})\text{NR}^{2a}\text{R}^{2b}$,
 $\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$, $\text{C}(\text{O})\text{NR}^2(\text{CH}_2)_r\text{OR}^2$, $\text{SO}_2\text{NR}^2\text{R}^{2a}$, $\text{NR}^2\text{SO}_2\text{R}^{2b}$, C₃₋₆
carbocycle **[carbocyclic residue]** substituted with 0-2
R⁴, and 5-10 membered **[heterocyclic system containing**
from] heterocycle consisting of carbon atoms and 1-4
heteroatoms selected from the group consisting of N, O,
and S substituted with 0-2 R⁴;

R¹ is selected from H, CH(CH₂OR²)₂, C(O)R^{2c}, C(O)NR²R^{2a}, S(O)R^{2b}, S(O)₂R^{2b}, and SO₂NR²R^{2a};

R², at each occurrence, is selected from H, CF₃, C₁₋₆ alkyl, benzyl, C₃₋₆ **carbocycle** [**carbocyclic residue**] substituted with 0-2 R^{4b}, and 5-6 membered [**heterocyclic system containing from**] **heterocycle consisting of carbon atoms and** 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

R^{2a}, at each occurrence, is selected from H, CF₃, C₁₋₆ alkyl, benzyl, phenethyl, C₃₋₆ **carbocycle** [**carbocyclic residue**] substituted with 0-2 R^{4b}, and 5-6 membered [**heterocyclic system containing from**] **heterocycle consisting of carbon atoms and** 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

R^{2b}, at each occurrence, is selected from CF₃, C₁₋₄ alkoxy, C₁₋₆ alkyl, benzyl, C₃₋₆ **carbocycle** [**carbocyclic residue**] substituted with 0-2 R^{4b}, and 5-6 membered [**heterocyclic system containing from**] **heterocycle consisting of carbon atoms and** 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

R^{2c}, at each occurrence, is selected from CF₃, OH, C₁₋₄ alkoxy, C₁₋₆ alkyl, benzyl, C₃₋₆ **carbocycle** [**carbocyclic residue**] substituted with 0-2 R^{4b}, and 5-6 membered [**heterocyclic system containing from**] **heterocycle consisting of carbon atoms and** 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

alternatively, R² and R^{2a}, together with the atom to which they are attached, combine to form a 5 or 6 membered

saturated, partially saturated or unsaturated ring substituted with 0-2 R^{4b} , [and] wherein [containing from] 0-1 additional ring heteroatoms selected from the group consisting of N, O, and S are present;

R^3 , at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

R^{3a} , at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

[R^{3b} , at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;]

R^{3c} , at each occurrence, is selected from C_{1-4} alkyl, and phenyl;

A is selected from:

C_{3-10} carbocycle [carbocyclic residue] substituted with 0-2 R^4 , and

5-10 membered [heterocyclic system containing from] heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^4 ;

B is selected from: H, Y, and X-Y;

X is selected from C_{1-4} alkylene, $-CR^2(CR^2R^{2b})(CH_2)_t-$, $-C(O)-$, $-C(=NR^{1''})-$, $-CR^2(NR^{1''}R^2)-$, $-CR^2(OR^2)-$, $-CR^2(SR^2)-$, $-C(O)CR^2R^{2a}-$, $-CR^2R^{2a}C(O)-$, $-S(O)_p-$, $-S(O)_pCR^2R^{2a}-$, $-CR^2R^{2a}S(O)_p-$, $-S(O)_2NR^2-$, $-NR^2S(O)_2-$, $-NR^2S(O)_2CR^2R^{2a}-$, $-CR^2R^{2a}S(O)_2NR^2-$, $-NR^2S(O)_2NR^2-$, $-C(O)NR^2-$, $-NR^2C(O)-$, $-C(O)NR^2CR^2R^{2a}-$, $-NR^2C(O)CR^2R^{2a}-$, $-CR^2R^{2a}C(O)NR^2-$, $-CR^2R^{2a}NR^2C(O)-$, $-NR^2C(O)O-$, $-OC(O)NR^2-$, $-NR^2C(O)NR^2-$, $-NR^2-$, $-NR^2CR^2R^{2a}-$, $-CR^2R^{2a}NR^2-$, O, $-CR^2R^{2a}O-$, and $-OCR^2R^{2a}-$;

Y is selected from:

$(\text{CH}_2)_r\text{NR}^2\text{R}^{2a}$, provided that X-Y do not form a N-N, O-N, or S-N bond,

C_{3-10} **carbocycle** [**carbocyclic residue**] substituted with 0-2 R^{4a} , and

5-10 membered [**heterocyclic system containing from** **heterocycle consisting of carbon atoms and** 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4a} ;

R^4 , at each occurrence, is selected from H, =O, $(\text{CH}_2)_r\text{OR}^2$, F, Cl, Br, I, C_{1-4} alkyl, -CN, NO_2 , $(\text{CH}_2)_r\text{NR}^2\text{R}^{2a}$, $(\text{CH}_2)_r\text{C}(\text{O})\text{R}^{2c}$, $\text{NR}^2\text{C}(\text{O})\text{R}^{2b}$, $\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$, $\text{NR}^2\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$, $\text{C}[\text{H}] (= \text{NR}^2)\text{NR}^2\text{R}^{2a}$, $\text{C}[\text{H}] (= \text{NS}(\text{O})_2\text{R}^5)\text{NR}^2\text{R}^{2a}$, $\text{NHC} (= \text{NR}^2)\text{NR}^2\text{R}^{2a}$, $\text{C}(\text{O})\text{NHC} (= \text{NR}^2)\text{NR}^2\text{R}^{2a}$, $\text{SO}_2\text{NR}^2\text{R}^{2a}$, $\text{NR}^2\text{SO}_2\text{NR}^2\text{R}^{2a}$, $\text{NR}^2\text{SO}_2\text{-C}_{1-4}$ alkyl, $\text{NR}^2\text{SO}_2\text{R}^5$, $\text{S}(\text{O})_p\text{R}^5$, $(\text{CF}_2)_r\text{CF}_3$, $\text{NCH}_2\text{R}^{1''}$, $\text{OCH}_2\text{R}^{1''}$, $\text{SCH}_2\text{R}^{1''}$, $\text{N}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1'}$, $\text{O}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1'}$, and $\text{S}(\text{CH}_2)_2(\text{CH}_2)_t\text{R}^{1'}$,

alternatively, one R^4 is a 5-6 membered aromatic heterocycle **consisting of carbon atoms and** [**containing from**] 1-4 heteroatoms selected from the group consisting of N, O, and S;

provided that if B is H, then R^4 is other than tetrazole, C(O)-alkoxy, and $\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$;

R^{4a} , at each occurrence, is selected from H, =O, $(\text{CH}_2)_r\text{OR}^2$, $(\text{CH}_2)_r\text{-F}$, $(\text{CH}_2)_r\text{-Br}$, $(\text{CH}_2)_r\text{-Cl}$, I, C_{1-4} alkyl, -CN, NO_2 , $(\text{CH}_2)_r\text{NR}^2\text{R}^{2a}$, $(\text{CH}_2)_r\text{NR}^2\text{R}^{2b}$, $(\text{CH}_2)_r\text{C}(\text{O})\text{R}^{2c}$, $\text{NR}^2\text{C}(\text{O})\text{R}^{2b}$, $\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$, $\text{C}(\text{O})\text{NH}(\text{CH}_2)_2\text{NR}^2\text{R}^{2a}$, $\text{NR}^2\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$, $\text{C}[\text{H}] (= \text{NR}^2)\text{NR}^2\text{R}^{2a}$, $\text{NHC} (= \text{NR}^2)\text{NR}^2\text{R}^{2a}$, $\text{SO}_2\text{NR}^2\text{R}^{2a}$, $\text{NR}^2\text{SO}_2\text{NR}^2\text{R}^{2a}$, $\text{NR}^2\text{SO}_2\text{-C}_{1-4}$ alkyl, $\text{C}(\text{O})\text{NHSO}_2\text{-C}_{1-4}$ alkyl, $\text{NR}^2\text{SO}_2\text{R}^5$, $\text{S}(\text{O})_p\text{R}^5$, and $(\text{CF}_2)_r\text{CF}_3$;

alternatively, one R^{4a} is a 5-6 membered aromatic heterocycle **consisting of carbon atoms and** [**containing from**] 1-4

heteroatoms selected from the group consisting of N, O, and S and substituted with 0-1 R⁵;

R^{4b}, at each occurrence, is selected from H, =O, (CH₂)_rOR³, F, Cl, Br, I, C₁₋₄ alkyl, -CN, NO₂, (CH₂)_rNR³R^{3a}, (CH₂)_rC(O)R³, (CH₂)_rC(O)OR^{3c}, NR³C(O)R^{3a}, C(O)NR³R^{3a}, NR³C(O)NR³R^{3a}, C[H](=NR³)NR³R^{3a}, NH³C(=NR³)NR³R^{3a}, SO₂NR³R^{3a}, NR³SO₂NR³R^{3a}, NR³SO₂-C₁₋₄ alkyl, NR³SO₂CF₃, NR³SO₂-phenyl, S(O)_pCF₃, S(O)_p-C₁₋₄ alkyl, S(O)_p-phenyl, and (CF₂)_rCF₃;

R⁵, at each occurrence, is selected from CF₃, C₁₋₆ alkyl, phenyl substituted with 0-2 R⁶, and benzyl substituted with 0-2 R⁶;

R⁶, at each occurrence, is selected from H, OH, (CH₂)_rOR², F, Cl, Br, I, C₁₋₄ alkyl, CN, NO₂, (CH₂)_rNR²R^{2a}, (CH₂)_rC(O)R^{2b}, NR²C(O)R^{2b}, NR²C(O)NR²R^{2a}, C[H](=NH)NH₂, NHC(=NH)NH₂, SO₂NR²R^{2a}, NR²SO₂NR²R^{2a}, and NR²SO₂C₁₋₄ alkyl;

[n is selected from 0, 1, 2, and 3;

m is selected from 0, 1, and 2;]

p is selected from 0, 1, and 2;

r is selected from 0, 1, 2, and 3;

s is selected from 0, 1, and 2; and,

t is selected from 0 and 1[.];

provided that when:

(a) ring D is furan, thiophene, pyrrole, isoxazole, isothiazole, or pyrazole, then Z is other than a bond; and,

(b) A is benzofuran, benzothiophene, indole, benzisoxazole, benzisothiazole, or indazole, then:

(i) ring M is pyrazole, or


(ii) Z is other than a bond or C₁₋₄ alkylene.

2. (Amended) A compound according to Claim 1, wherein:

D-E is selected from the group:

1-aminoisoquinolin-7-yl; 1,3-diaminoisoquinolin-7-yl; 1,4-diaminoisoquinolin-7-yl; 1,5-diaminoisoquinolin-7-yl; 1,6-diaminoisoquinolin-7-yl; 1-amino-3-hydroxy-isoquinolin-7-yl; 1-amino-4-hydroxy-isoquinolin-7-yl; 1-amino-5-hydroxy-isoquinolin-7-yl; 1-amino-6-hydroxy-isoquinolin-7-yl; 1-amino-3-methoxy-isoquinolin-7-yl; 1-amino-4-methoxy-isoquinolin-7-yl; 1-amino-5-methoxy-isoquinolin-7-yl; 1-amino-6-methoxy-isoquinolin-7-yl; 1-hydroxy-isoquinolin-7-yl; 4-aminoquinazol-6-yl; 2,4-diaminoquinazol-6-yl; 4,7-diaminoquinazol-6-yl; 4,8-diaminoquinazol-6-yl; 1-aminophthalaz-7-yl; 1,4-diaminophthalaz-7-yl; 1,5-diaminophthalaz-7-yl; 1,6-diaminophthalaz-7-yl; 4-aminopterid-6-yl; 2,4-aminopterid-6-yl; 4,6-diaminopterid-6-yl; 8-amino-1,7-naphthyrid-2-yl; 6,8-diamino-1,7-naphthyrid-2-yl; 5,8-diamino-1,7-naphthyrid-2-yl; 4,8-diamino-1,7-naphthyrid-2-yl; 3,8-diamino-1,7-naphthyrid-2-yl; 5-amino-2,6-naphthyrid-3-yl; 5,7-diamino-2,6-naphthyrid-3-yl; 5,8-diamino-2,6-naphthyrid-3-yl; 1,5-diamino-2,6-naphthyrid-3-yl; 5-amino-1,6-naphthyrid-3-yl; 5,7-diamino-1,6-naphthyrid-3-yl; 5,8-diamino-1,6-naphthyrid-3-yl; 2,5-diamino-1,6-naphthyrid-3-yl; 3-aminoindazol-5-yl; 3-hydroxyindazol-5-yl; 3-aminobenzisoxazol-5-yl; 3-hydroxybenzisoxazol-5-yl; 3-aminobenzisothiazol-5-yl; 3-hydroxybenzisothiazol-5-yl; 1-amino-3,4-dihydroisoquinolin-7-yl; and, 1-aminoisoindol-6-yl;

M is selected from the group:




Z is selected from $(CH_2)_rC(O)(CH_2)_r$, $(CH_2)_rC(O)O(CH_2)_r$, $(CH_2)_rC(O)NR^3(CH_2)_r$, $(CH_2)_rS(O)_p(CH_2)_r$, and $(CH_2)_rSO_2NR^3(CH_2)_r$; and,

Y is selected from one of the following rings [carbocyclic and heterocyclic systems] which are substituted with 0-2 R^{4a};

phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazole, thiadiazole, triazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, benzofuran, benzothiofuran, indole, benzimidazole, benzoxazole, benzthiazole, indazole, benzisoxazole, benzisothiazole, and isoindazole;

alternatively, Y is [Y may also be] selected from the following bicyclic heteroaryl ring systems:



K is selected from O, S, NH, and N.


3. (Amended) A compound according to Claim 2, wherein:

D-E is selected from the group:

1-aminoisoquinolin-7-yl; 1,3-diaminoisoquinolin-7-yl; 1,4-diaminoisoquinolin-7-yl; 1,5-diaminoisoquinolin-7-yl; 1,6-diaminoisoquinolin-7-yl; 1-hydroxy-isoquinolin-7-yl; 4-aminoquinazol-6-yl; 2,4-diaminoquinazol-6-yl; 4,7-diaminoquinazol-6-yl; 4,8-diaminoquinazol-6-yl; 1-aminophthalaz-7-yl; 1,4-diaminophthalaz-7-yl; 1,5-diaminophthalaz-7-yl; 1,6-

diaminophthalaz-7-yl; 4-aminopterid-6-yl; 8-amino-1,7-naphthyrid-2-yl; 5-amino-1,6-naphthyrid-3-yl; 5-amino-2,6-naphthyrid-3-yl; 3-aminobenzisoxazol-5-yl; 3-aminobenzisothiazol-5-yl; 1-amino-3,4-dihydroisoquinolin-7-yl; and, 1-aminoisoindol-6-yl;

M is selected from the group:



Z is selected from $(\text{CH}_2)_r\text{C}(\text{O})(\text{CH}_2)_r$ and $(\text{CH}_2)_r\text{C}(\text{O})\text{NR}^3(\text{CH}_2)_r$; and,

Y is selected from one of the following rings [carbocyclic and heterocyclic systems] which are substituted with 0-2 R^{4a};


phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazole, thiadiazole, triazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, benzofuran, benzothiofuran, indole, benzimidazole, benzoxazole, benzthiazole, indazole, benzisoxazole, benzisothiazole, and isoindazole.

4. (Amended) A compound according to Claim 3, wherein:

D-E is selected from the group:

1-aminoisoquinolin-7-yl; 1,3-diaminoisoquinolin-7-yl; 1,4-diaminoisoquinolin-7-yl; 1,5-diaminoisoquinolin-7-yl; 1,6-diaminoisoquinolin-7-yl; 1-aminophthalaz-7-yl; 1,4-diaminophthalaz-7-yl; 1,5-diaminophthalaz-7-yl; 1,6-diaminophthalaz-7-yl; 4-aminopterid-6-yl; 8-amino-1,7-naphthyrid-2-yl; 5-amino-1,6-naphthyrid-3-y; 5-amino-2,6-naphthyrid-3-yl; 3-aminobenzisoxazol-5-yl; 1-amino-3,4-dihydroisoquinolin-7-yl; and, 1-aminoisoindol-6-yl;

M is selected from the group:



A is selected from:

C₅₋₆ **carbocycle** [carbocyclic residue] substituted with 0-2 R⁴, and

5-6 membered [heterocyclic system containing from] **heterocycle consisting of carbon atoms and** 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R⁴;

Y is selected from one of the following **rings** [carbocyclic and heterocyclic systems] which are substituted with 0-2 R^{4a};

phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, benzimidazolyl, oxadiazole, thiadiazole, triazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, and 1,3,4-triazole;

R², at each occurrence, is selected from H, CF₃, C₁₋₆ alkyl, benzyl, C₅₋₆ **carbocycle** [carbocyclic residue] substituted with 0-2 R^{4b}, and 5-6 membered [heterocyclic system containing from] **heterocycle consisting of carbon atoms and** 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

R^{2a}, at each occurrence, is selected from H, CF₃, C₁₋₆ alkyl, benzyl, phenethyl, C₅₋₆ carbocycle [carbocyclic residue] substituted with 0-2 R^{4b}, and 5-6 membered [heterocyclic system containing from] heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

R^{2b}, at each occurrence, is selected from CF₃, C₁₋₄ alkoxy, C₁₋₆ alkyl, benzyl, C₅₋₆ carbocycle [carbocyclic residue] substituted with 0-2 R^{4b}, and 5-6 membered [heterocyclic system containing from] heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

R^{2c}, at each occurrence, is selected from CF₃, OH, C₁₋₄ alkoxy, C₁₋₆ alkyl, benzyl, C₅₋₆ carbocycle [carbocyclic residue] substituted with 0-2 R^{4b}, and 5-6 membered [heterocyclic system containing from] heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

alternatively, R² and R^{2a}, together with the atom to which they are attached, combine to form a ring selected from imidazolyl, morpholino, piperazinyl, pyridyl, and pyrrolidinyl, substituted with 0-2 R^{4b};

R⁴, at each occurrence, is selected from H, =O, OR², CH₂OR², F, Cl, C₁₋₄ alkyl, NR²R^{2a}, CH₂NR²R^{2a}, C(O)R^{2c}, CH₂C(O)R^{2c}, C(O)NR²R^{2a}, C[H](=NR²)NR²R^{2a}, C[H](=NS(O)₂R⁵)NR²R^{2a}, SO₂NR²R^{2a}, NR²SO₂-C₁₋₄ alkyl, S(O)₂R⁵, and CF₃

provided that if B is H, then R⁴ is other than tetrazole, C(O)-alkoxy, and C(O)NR²R^{2a};

R^{4a}, at each occurrence, is selected from H, =O, (CH₂)_rOR², F, Cl, C₁₋₄ alkyl, NR²R^{2a}, CH₂NR²R^{2a}, NR²R^{2b}, CH₂NR²R^{2b}, (CH₂)_rC(O)R^{2c}, NR²C(O)R^{2b}, C(O)NR²R^{2a}, C(O)NH(CH₂)₂NR²R^{2a}, NR²C(O)NR²R^{2a}, SO₂NR²R^{2a}, S(O)₂R⁵, and CF₃; and,

R^{4b}, at each occurrence, is selected from H, =O, (CH₂)_rOR³, F, Cl, C₁₋₄ alkyl, NR³R^{3a}, CH₂NR³R^{3a}, C(O)R³, CH₂C(O)R³, C(O)OR^{3c}, C(O)NR³R^{3a}, C[**H**] (=NR³)NR³R^{3a}, SO₂NR³R^{3a}, NR³SO₂-C₁₋₄ alkyl, NR³SO₂CF₃, NR³SO₂-phenyl, S(O)₂CF₃, S(O)₂-C₁₋₄ alkyl, S(O)₂-phenyl, and CF₃.

6. (Amended) A compound according to Claim 1, wherein the compound is selected from:

1-(1'-Amino-isoquinol-7'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;

1-(1'-Amino-isoquinol-7'-yl)-3-methyl-5-[(2'-methylsulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;

1-(4'-Amino-isoquinol-7'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;

1-(Isoquinol-7'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;

3-(1'-Amino-isoquinol-7'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]-5-methylisoxazoline;

3-(Isoquinol-5'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]-5-methylisoxazoline;

3-(Isoquinol-7'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]-5-methylisoxazoline;

3-(2'-Aminobenzimidazol-5'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-methylisoxazoline;

3-(3'-Aminoindazol-5'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-methylisoxazoline;

3-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-methylisoxazoline

- [1-(3'-Aminobenzisoxazol-5'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;]**
- 3-(1-Amino-isoquinol-7-yl)-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,2,3-triazole;
- 3-(4-amino-isoquinol-7-yl)-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,2,3-triazole;
- 3-(isoquinol-7-yl)-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-1,2,3-triazole;
- 1-(Quinol-2-ylmethyl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(Quinol-2-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- [1-(3'-Aminoindazol-5'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;**
- 1-(3-Aminoindazole-5-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;**
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-methyl-5-[(2'-aminosulfonyl-(phenyl)pyrid-2-ylaminocarbonyl]pyrazole;**
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-methyl-5-[isoquinol-7-yl)aminocarbonyl]pyrazole;]**
- 1-(1'-Aminoisoquinol-7'-yl)-3-ethyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-isopropyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(2',4'-Diaminoquinazol-6'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(4'-Aminoquinazol-6'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-methyl-5-[4-(N-pyrrolidinylcarbonyl)phenylaminocarbonyl]pyrazole;

- [1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;]
- 1-(1'-Aminophthalazin-7'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 3-(3'-Aminobenzisoxazol-5'-yl)-5-[[5-[(2'-aminosulfonyl)phenyl]pyrid-2-yl]aminocarbonyl]-5-(methylsulfonylaminomethyl)isoxazoline;
- [1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2-fluoro-4-morpholinophenyl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[4-(2'-isopropylimidazol-1'-yl)phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[4-(2'-ethylimidazol-1'-yl)phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[4-[(2'-dimethylaminomethyl)imidazol-1'-yl]phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[4-[(2'-methoxymethyl)imidazol-1'-yl]phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[4-[(2'-dimethylaminomethyl)imidazol-1'-yl]-2-fluorophenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[[(2-methoxy-4-(2'-methylimidazol-1'-yl)phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[4-(2'-isopropylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[[4-(2'-ethylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[4-(2'-ethylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]pyrazole;

- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[4-[(2'-methoxymethyl)imidazol-1'-yl]phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[4-[(2'-dimethylaminomethyl)imidazol-1'-yl]phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[4-[(2'-methyl)benzimidazol-1'-yl]phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[(2'-ethylimidazol-1'-yl)phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[4-(2'-ethylimidazol-1'-yl)-2,5-difluorophenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[(2-fluoro-4-morpholinophenyl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[(2'-isopropylimidazol-1'-yl)phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[4-(2'-methylimidazol-1'-yl)-2-fluorophenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[(2'-aminosulfonyl-3-amino-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[(2'-aminosulfonyl-3-nitro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[4-(2'-methylimidazol-1'-yl)phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[2-dimethyl-4-(N-pyrrolidinocarbonyl)phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[2-pyrrolidino-4-(N-pyrrolidinocarbonyl)phenyl]-aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[2-fluoro-4-(N-pyrrolidinocarbonyl)phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;

- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[5-[(2'-methylsulfonyl)phenyl]pyrimid-2-yl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[[(2'-methylsulfonyl)-3-fluoro-[1,1']-biphen-4-yl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[[5-[(2'-aminosulfonyl)phenyl]pyrid-2-yl]aminocarbonyl]pyrazole;]
- 1-(3'-Aminobenzisoxazol-5'-yl)-5-[[[(2'-methylsulfonyl)-3-fluoro-[1,1']-biphen-4-yl]aminocarbonyl]tetrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-5-[[4-(2'-methyylimidazol-1'-yl)phenyl]aminocarbonyl]tetrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]tetrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2-fluoro-4-(N-pyrrolidinocarbonyl)phenyl)aminocarbonyl]tetrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2-(N-pyrrolidino)-4-(N-pyrrolidinocarbonyl)phenyl)aminocarbonyl]tetrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-5-[[[(2'-aminosulfonyl)-3-fluoro-[1,1']-biphen-4-yl]aminocarbonyl]tetrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-5-[[[(2'-methylsulfonyl)-3-fluoro-[1,1']-biphen-4-yl]aminocarbonyl]tetrazole;
- [1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-aminosulfonylphenyl)pyrimidin-2-yl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[4-(2'-methyylimidazol-1'-yl)phenyl]aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[4-(2'-methyylimidazol-1'-yl)-2-fluorophenyl)-aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[4-(1'-methyylimidazol-2'-yl)-2-fluorophenyl]amino-carbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[4-(2'-aminoimidazol-1'-yl)phenyl]aminocarbonyl]pyrazole;

1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-dimethylaminomethyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;

Ethyl 1-(3'-aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole-3-carboxylate;

1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole-3-carboxylic acid;

1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole-3-carboxamide;

Ethyl 1-(3'-aminobenzisoxazol-5'-yl)-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole-3-carboxylate;

1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole-3-carboxylic acid;

1-(3'-Aminobenzisoxazol-5'-yl)-3-(hydroxymethyl)-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;

1-(3'-Aminobenzisoxazol-5'-yl)-3-[dimethylaminomethyl]-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;

Ethyl 1-(3'-aminobenzisoxazol-5'-yl)-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole-4-carboxylate;

1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole-4-carboxylic acid;

1-(1',2',3',4'-Tetrahydroisoquinol-7'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;

1-(1'-Amino-isoquinol-7'-yl)-3-[(2'-methylaminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]-5-methylpyrazole;

1-(4'-Amino-isoquinol-7'-yl)-3-methyl-5-[(2'-methylsulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;

- 1-(1'-Amino-isoquinol-7'-yl)-3-trifluoromethyl-5-[(2'-methylsulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-trifluoromethyl-5-[(2-fluoro-4-(N-pyrrolidinocarbonyl)-phenyl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-trifluoromethyl-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-trifluoromethyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-trifluoromethyl-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-trifluoromethyl-5-[(5-(2'-methylsulfonylphenyl)pyrid-2-yl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-methyl-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-methyl-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-trifluoromethyl-5-[(2'-aminosulfonyl-3-chloro-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-trifluoromethyl-5-[(2'-aminosulfonyl-3-methyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 1-(1'-Amino-isoquinol-7'-yl)-3-trifluoromethyl-5-[(2'-methylaminosulfonyl-[1,1']-biphen-4-yl)carbonylamino]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-ethyl-5-[(2'-methylaminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-ethyl-5-[(2'-methylsulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;

- 1-(1'-Aminoisoquinol-7'-yl)-3-propyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-propyl-5-[(2'-methylaminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-propyl-5-[(2'-methylsulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-ethyl-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-ethyl-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-ethyl-5-[4-(N-pyrrolidinocarbonyl-1-yl)phenylaminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-trifluoromethyl-5-[4-(imidazol-1'-yl)phenylaminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-trifluoromethyl-5-[3-fluoro-4-(2-methylimidazol-1'-yl)phenylaminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-trifluoromethyl-5-[4-(2-methylimidazol-1'-yl)phenylaminocarbonyl]pyrazole;
- 1-(1'-Aminoisoquinol-7'-yl)-3-trifluoromethyl-5-[2-fluoro-4-(2-methylimidazol-1'-yl)phenylaminocarbonyl]pyrazole;
- [1-(3'-Aminobenzisoxazol-5'-yl)-3-methyl-5-[(2'-methylsulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;**
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;**
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[2-fluoro-4-(N-pyrrolidinocarbonyl)phenylaminocarbonyl]pyrazole;**
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(5-(2'-aminosulfonylphenyl)pyrid-2-yl)aminocarbonyl]pyrazole;**
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(5-(2'-methylsulfonylphenyl)pyrimid-2-yl)aminocarbonyl]pyrazole;**

- 1-(3'-Aminobenzisoxazol-5'-yl)-3-methyl-5-[(4-(pyrid-3'-yl)phenyl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(4-(pyrid-3'-yl-3-fluorophenyl)aminocarbonyl]pyrazole;
- 1-(3'-Aminoindazol-5'-yl)-3-trifluoromethyl-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminoindazol-5'-yl)-3-trifluoromethyl-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminoindazol-5'-yl)-3-trifluoromethyl-5-[2-fluoro-4-(N-pyrrolidinocarbonyl)phenylaminocarbonyl]pyrazole;
- 1-(3'-Aminoindazol-5'-yl)-3-methyl-5-[(4-(pyrid-3'-yl)phenyl)aminocarbonyl]pyrazole;
- 1-(3'-Aminoindazol-5'-yl)-3-trifluoromethyl-5-[(4-(pyrid-3'-yl-3-fluorophenyl)aminocarbonyl]pyrazole;]
- 1-(3'-Aminomethylnaphth-2'-yl)-3-trifluoromethyl-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole; and,
- [1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-hydroxymethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-methylaminomethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-bromomethyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-pyridiniummethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-aminomethyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;

- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-imidazol-1''-yl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-(4''-t-butoxycarbonyl)piperazin-1''-ylmethyl)-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-(N,N-dimethylamino)pyridiniummethyl)-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-piperazin-1''-ylmethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-N-methylmorpholiniummethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-morpholinomethyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(3-fluoro-2'-(N-methyl-N-methoxyamino)-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;]
- 1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]triazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-aminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]triazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-methylaminosulfonyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-5-[(2'-dimethylaminomethyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]tetrazole;
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[(2'-dimethylaminomethyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole; and,
- 1-(3'-Aminobenzisoxazol-5'-yl)-3-ethyl-5-[4'-(2''-dimethylaminomethylimidazol-1''-yl)-2'-fluorophenyl)aminocarbonyl]pyrazole;

or pharmaceutically acceptable salt thereof.

13. (Amended) A method for treating **[or preventing]** a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

14. (Amended) A method for treating **[or preventing]** a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 2 or a pharmaceutically acceptable salt thereof.

15. (Amended) A method for treating **[or preventing]** a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 3 or a pharmaceutically acceptable salt thereof.

16. (Amended) A method for treating **[or preventing]** a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 4 or a pharmaceutically acceptable salt thereof.

17. (Amended) A method for treating **[or preventing]** a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 5 or a pharmaceutically acceptable salt thereof.

18. (Amended) A method for treating **[or preventing]** a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount

of a compound according to Claim 6 or a pharmaceutically acceptable salt thereof.